28. Discovery and Development of Entecavir

  1. Wieslaw M. Kazmierski
  1. Richard Wilber,
  2. Bruce Kreter,
  3. Marc Bifano,
  4. Stephanie Danetz,
  5. Lois Lehman-McKeeman,
  6. Daniel J. Tenney,
  7. Nicholas Meanwell,
  8. Robert Zahler and
  9. Helena Brett-Smith

Published Online: 20 JUN 2011

DOI: 10.1002/9780470929353.ch28

Antiviral Drugs: From Basic Discovery through Clinical Trials

Antiviral Drugs: From Basic Discovery through Clinical Trials

How to Cite

Wilber, R., Kreter, B., Bifano, M., Danetz, S., Lehman-McKeeman, L., Tenney, D. J., Meanwell, N., Zahler, R. and Brett-Smith, H. (2011) Discovery and Development of Entecavir, in Antiviral Drugs: From Basic Discovery through Clinical Trials (ed W. M. Kazmierski), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470929353.ch28

Author Information

  1. Bristol-Myers Squibb Company Research and Development, Wallingford, Connecticut, USA

Publication History

  1. Published Online: 20 JUN 2011
  2. Published Print: 8 AUG 2011

ISBN Information

Print ISBN: 9780470455630

Online ISBN: 9780470929353

SEARCH

Keywords:

  • entecavir, program, Bristol-Myers Squibb (BMS) - hepatitis B infection, public health problem;
  • duck hepatitis B virus (DHBV) - entecavir, efficacy in DHBV as postexposure HBV therapy;
  • combination regimens, role - in future of CHB treatment

Summary

This chapter contains sections titled:

  • Introduction

  • Discovery

  • Synthesis

  • Preclinical Toxicology

  • Animal Models

  • Phase I-III Safety and Efficacy

  • In Vitro Activity and Resistance

  • Future Directions

  • References